Related Experiment Video

Updated: May 29, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Update on prostate cancer vaccines

Charles G Drake1

  • 1Johns Hopkins Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA. cdrake@jhmi.edu

Cancer Journal (Sudbury, Mass.)
|September 29, 2011
PubMed

Insights

The first FDA-approved prostate cancer vaccine, Sipuleucel-T, marks a milestone in cancer immunotherapy. Research is ongoing into various vaccine types, including viral vectors, dendritic cells, and DNA vaccines, for treating prostate cancer.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Sipuleucel-T, the first FDA-approved cancer vaccine for prostate cancer, signifies a breakthrough in immunotherapy.
  • Prostate cancer is recognized as an immunologically responsive malignancy, driving further research.
  • The approval has stimulated significant interest in developing novel cancer vaccines.

Purpose of the Study:

  • To review the fundamental technologies behind different prostate cancer vaccine approaches.
  • To summarize completed and ongoing clinical trials for prostate cancer vaccines.
  • To focus on vaccines currently in clinical trials, based on database inquiries.

Main Methods:

  • Review of scientific literature and clinical trial data.
  • Analysis of vaccine technologies: viral vectors, dendritic cells, and DNA vaccines.
  • Focus on clinical trials identified through www.clinicaltrials.gov.

Main Results:

  • Multiple prostate cancer vaccine strategies are under active clinical investigation.
  • Each vaccine approach (viral, dendritic cell, DNA) presents unique benefits and challenges.
  • A comprehensive overview of current clinical trial landscape for prostate cancer vaccines is provided.

Conclusions:

  • The development of cancer vaccines for prostate cancer is a rapidly evolving field.
  • Ongoing clinical trials are exploring diverse technological platforms for enhanced efficacy.
  • Further research and clinical evaluation are crucial for advancing prostate cancer immunotherapy.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...